Chapter 32: Drugs for Hematopoietic Disorders
Question 1
Type: MCMA
The client receives epoetin alfa (Epogen) subcutaneously, and says to the nurse, "My doctor said I have anemia.
Are there little red blood cells in that shot?" What are the best responses by the nurse?
1. "No, we do not give blood for anemia anymore."
2. "No, this medication stimulates your body to make red blood cells."
3. " Yes, this small amount of red blood cells will stimulate your bone marrow to produce more cells in the
kidney.” 4. "No, this medication promotes clotting so you will not lose even more red blood cells.”
Correct Answer: 2
Rationale 1: Blood transfusions are given if anemia is severe.
Rationale 2: The nurse should explain how the epoetin alfa (Epogen) works.
Rationale 3: Epoetin alfa (Epogen) is not red blood cells.
Rationale 4: Epoetin alfa (Epogen) is not a clot promoter.
Global Rationale: The nurse should explain how the epoetin alfa (Epogen) works. Blood transfusions are given if
anemia is severe. Epoetin alfa (Epogen) is not red blood cells and is not a clot promoter.
Cognitive Level: Applying
Client Need: Physiological Integrity
Client Need Sub: Physiological Adaptation
QSEN Competencies: III.A.1 Demonstrate knowledge of basic scientific methods and processes.
AACN Essentials Competencies: III.1 Explain the interrelationships among theory, practice, and research.
NLN Competencies: Knowledge and Science: Integration of knowledge from nursing and other disciplines.
Nursing/Integrated Concepts: Nursing Process: Implementation
Learning Outcome: 32-2 Explain how aspects of hematopoiesis can be modified by the administration of drugs
that stimulate the production of erythrocytes, leukocytes, and platelets.
MNL Learning Outcome: 4.6.1 Examine the process of hematopoiesis and the pharmacologic treatment of
related deficiencies.
Page Number: 484
Question 2
Type: MCSA
,The nurse is teaching a class on how red blood cell formation is regulated by the body to a group of clients who
have AIDS. The nurse evaluates that learning has occurred when the clients make which statements?
1. "Red blood cell formation is regulated through chemicals called colony-stimulating factors that come from
white blood cells."
2. "Red blood cell formation is regulated through messages from the hormone, secretin, which is located in the
kidney."
3. "Red blood cell formation is regulated through specific liver enzymes and a process called hemochromatosis."
4. "Red blood cell formation is regulated through messages from the hormone erythropoietin."
Correct Answer: 4
Rationale 1: Colony-stimulating factors affect white blood cell production.
Rationale 2: Secretin stimulates the pancreas to release a fluid that neutralizes stomach acid and aids in
digestion; it has nothing to do with red blood cell formation.
Rationale 3: Hemochromatosis refers to excess iron accumulation in the body, not to red blood cell formation.
Rationale 4: Regulation of hematopoiesis occurs through messages from hormones such as erythropoietin.
Global Rationale: Regulation of hematopoiesis occurs through messages from hormones such as erythropoietin.
Colony-stimulating factors affect white blood cell production. Secretin stimulates the pancreas to release a fluid
that neutralizes stomach acid and aids in digestion; it has nothing to do with red blood cell formation.
Hemochromatosis refers to excess iron accumulation in the body, not to red blood cell formation.
Cognitive Level: Applying
Client Need: Physiological Integrity
Client Need Sub: Physiological Adaptation
QSEN Competencies: III.A.1 Demonstrate knowledge of basic scientific methods and processes.
AACN Essentials Competencies: III.1 Explain the interrelationships among theory, practice, and research.
NLN Competencies: Knowledge and Science: Integration of knowledge from nursing and other disciplines.
Nursing/Integrated Concepts: Nursing Process: Evaluation Learning Outcome: 32-1 Describe the process
of hematopoiesis.
MNL Learning Outcome: 4.6.1 Examine the process of hematopoiesis and the pharmacologic treatment of
related deficiencies.
Page Number: 484
Question 3
Type: MCSA
The client receives chemotherapy as therapy for cancer. The physician orders epoetin alfa (Procrit)
subcutaneously. The client asks the nurse if this drug is also chemotherapy. What is the best response by the
nurse?
,1. "No, but it works with your chemotherapy to make it more effective."
2. "No, this drug helps to counteract the nausea and vomiting caused by your chemotherapy."
3. "No, it will stimulate your immune system to help you battle the cancer."
4. "No, this drug will help prevent anemia that can be caused by your chemotherapy."
Correct Answer: 4
Rationale 1: Epoetin alfa (Procrit) is prescribed to treat anemia associated with chemotherapy; it does not make
the chemotherapy more effective.
Rationale 2: Epoetin alfa (Procrit) is prescribed to treat anemia associated with chemotherapy; it does not
counteract nausea and vomiting.
Rationale 3: Epoetin alfa (Procrit) is prescribed to treat anemia associated with chemotherapy; it does not
stimulate the immune system.
Rationale 4: Epoetin alfa (Procrit) is given to clients undergoing cancer chemotherapy to counteract the anemia
caused by antineoplastic agents.
Global Rationale: Epoetin alfa (Procrit) is given to clients undergoing cancer chemotherapy to counteract the
anemia caused by antineoplastic agents. It does not make chemotherapy more effective, counteract nausea and
vomiting, or stimulate the immune system.
Cognitive Level: Applying
Client Need: Physiological Integrity
Client Need Sub: Pharmacological and Parenteral Therapies
QSEN Competencies: III.A.1 Demonstrate knowledge of basic scientific methods and processes.
AACN Essentials Competencies: III.1 Explain the interrelationships among theory, practice, and research.
NLN Competencies: Knowledge and Science: Integration of knowledge from nursing and other disciplines.
Nursing/Integrated Concepts: Nursing Process: Implementation
Learning Outcome: 32-3 Explain why hematopoietic enhancers are often administered to patients following
chemotherapy or organ transplant.
MNL Learning Outcome: 4.6.1 Examine the process of hematopoiesis and the pharmacologic treatment of
related deficiencies.
Page Number: 485
Question 4
Type: MCSA
The client receives filgrastim (Neupogen). He asks the nurse, "That is such a funny name; where do you suppose
it comes from?" What is the best response by the nurse?
1. "It comes from the interleukins it stimulates; this one stimulates neuocytes."
, 2. "It comes from the blood cell it stimulates; this one stimulates neutrophils."
3. "It comes from the stem cells it stimulates, such as filgrastims."
4. "It is a complicated process; the drug companies are secretive about it."
Correct Answer: 2
Rationale 1: There aren't any interleukins named neuocytes.
Rationale 2: Colony-stimulating factors (CSFs) are named according to the types of blood cells that they
stimulate. Granulocyte colony-stimulating factor (G-CSF) increases the production of neutrophils, the most
common type of granulocyte.
Rationale 3: There aren't any stem cells named filgrastims.
Rationale 4: Naming of drugs is not a complicated process.
Global Rationale: Colony-stimulating factors (CSFs) are named according to the types of blood cells that they
stimulate. Granulocyte colony-stimulating factor (G-CSF) increases the production of neutrophils, the most
common type of granulocyte. There aren't any interleukins named neuocytes. There aren't any stem cells named
filgrastims. Naming of drugs is not a complicated process.
Cognitive Level: Applying
Client Need: Physiological Integrity
Client Need Sub: Pharmacological and Parenteral Therapies
QSEN Competencies: III.A.1 Demonstrate knowledge of basic scientific methods and processes.
AACN Essentials Competencies: III.1 Explain the interrelationships among theory, practice, and research.
NLN Competencies: Knowledge and Science: Integration of knowledge from nursing and other disciplines.
Nursing/Integrated Concepts: Nursing Process: Implementation
Learning Outcome: 32-2 Explain how aspects of hematopoiesis can be modified by the administration of drugs
that stimulate the production of erythrocytes, leukocytes, and platelets.
MNL Learning Outcome: 4.6.1 Examine the process of hematopoiesis and the pharmacologic treatment of
related deficiencies.
Page Number: 484
Question 5
Type: MCSA
The client is receiving medication for the treatment of anemia. The nurse has taught the client about this drug
and about anemia. The nurse evaluates that learning has occurred when the client makes which statement?
1. "My anemia could be caused by blood loss somewhere, but there are other causes too."
2. "My anemia was caused by drinking too many carbonated beverages with caffeine."
3. "There are many causes for anemia; mine was caused by heart failure and fluid overload."
Question 1
Type: MCMA
The client receives epoetin alfa (Epogen) subcutaneously, and says to the nurse, "My doctor said I have anemia.
Are there little red blood cells in that shot?" What are the best responses by the nurse?
1. "No, we do not give blood for anemia anymore."
2. "No, this medication stimulates your body to make red blood cells."
3. " Yes, this small amount of red blood cells will stimulate your bone marrow to produce more cells in the
kidney.” 4. "No, this medication promotes clotting so you will not lose even more red blood cells.”
Correct Answer: 2
Rationale 1: Blood transfusions are given if anemia is severe.
Rationale 2: The nurse should explain how the epoetin alfa (Epogen) works.
Rationale 3: Epoetin alfa (Epogen) is not red blood cells.
Rationale 4: Epoetin alfa (Epogen) is not a clot promoter.
Global Rationale: The nurse should explain how the epoetin alfa (Epogen) works. Blood transfusions are given if
anemia is severe. Epoetin alfa (Epogen) is not red blood cells and is not a clot promoter.
Cognitive Level: Applying
Client Need: Physiological Integrity
Client Need Sub: Physiological Adaptation
QSEN Competencies: III.A.1 Demonstrate knowledge of basic scientific methods and processes.
AACN Essentials Competencies: III.1 Explain the interrelationships among theory, practice, and research.
NLN Competencies: Knowledge and Science: Integration of knowledge from nursing and other disciplines.
Nursing/Integrated Concepts: Nursing Process: Implementation
Learning Outcome: 32-2 Explain how aspects of hematopoiesis can be modified by the administration of drugs
that stimulate the production of erythrocytes, leukocytes, and platelets.
MNL Learning Outcome: 4.6.1 Examine the process of hematopoiesis and the pharmacologic treatment of
related deficiencies.
Page Number: 484
Question 2
Type: MCSA
,The nurse is teaching a class on how red blood cell formation is regulated by the body to a group of clients who
have AIDS. The nurse evaluates that learning has occurred when the clients make which statements?
1. "Red blood cell formation is regulated through chemicals called colony-stimulating factors that come from
white blood cells."
2. "Red blood cell formation is regulated through messages from the hormone, secretin, which is located in the
kidney."
3. "Red blood cell formation is regulated through specific liver enzymes and a process called hemochromatosis."
4. "Red blood cell formation is regulated through messages from the hormone erythropoietin."
Correct Answer: 4
Rationale 1: Colony-stimulating factors affect white blood cell production.
Rationale 2: Secretin stimulates the pancreas to release a fluid that neutralizes stomach acid and aids in
digestion; it has nothing to do with red blood cell formation.
Rationale 3: Hemochromatosis refers to excess iron accumulation in the body, not to red blood cell formation.
Rationale 4: Regulation of hematopoiesis occurs through messages from hormones such as erythropoietin.
Global Rationale: Regulation of hematopoiesis occurs through messages from hormones such as erythropoietin.
Colony-stimulating factors affect white blood cell production. Secretin stimulates the pancreas to release a fluid
that neutralizes stomach acid and aids in digestion; it has nothing to do with red blood cell formation.
Hemochromatosis refers to excess iron accumulation in the body, not to red blood cell formation.
Cognitive Level: Applying
Client Need: Physiological Integrity
Client Need Sub: Physiological Adaptation
QSEN Competencies: III.A.1 Demonstrate knowledge of basic scientific methods and processes.
AACN Essentials Competencies: III.1 Explain the interrelationships among theory, practice, and research.
NLN Competencies: Knowledge and Science: Integration of knowledge from nursing and other disciplines.
Nursing/Integrated Concepts: Nursing Process: Evaluation Learning Outcome: 32-1 Describe the process
of hematopoiesis.
MNL Learning Outcome: 4.6.1 Examine the process of hematopoiesis and the pharmacologic treatment of
related deficiencies.
Page Number: 484
Question 3
Type: MCSA
The client receives chemotherapy as therapy for cancer. The physician orders epoetin alfa (Procrit)
subcutaneously. The client asks the nurse if this drug is also chemotherapy. What is the best response by the
nurse?
,1. "No, but it works with your chemotherapy to make it more effective."
2. "No, this drug helps to counteract the nausea and vomiting caused by your chemotherapy."
3. "No, it will stimulate your immune system to help you battle the cancer."
4. "No, this drug will help prevent anemia that can be caused by your chemotherapy."
Correct Answer: 4
Rationale 1: Epoetin alfa (Procrit) is prescribed to treat anemia associated with chemotherapy; it does not make
the chemotherapy more effective.
Rationale 2: Epoetin alfa (Procrit) is prescribed to treat anemia associated with chemotherapy; it does not
counteract nausea and vomiting.
Rationale 3: Epoetin alfa (Procrit) is prescribed to treat anemia associated with chemotherapy; it does not
stimulate the immune system.
Rationale 4: Epoetin alfa (Procrit) is given to clients undergoing cancer chemotherapy to counteract the anemia
caused by antineoplastic agents.
Global Rationale: Epoetin alfa (Procrit) is given to clients undergoing cancer chemotherapy to counteract the
anemia caused by antineoplastic agents. It does not make chemotherapy more effective, counteract nausea and
vomiting, or stimulate the immune system.
Cognitive Level: Applying
Client Need: Physiological Integrity
Client Need Sub: Pharmacological and Parenteral Therapies
QSEN Competencies: III.A.1 Demonstrate knowledge of basic scientific methods and processes.
AACN Essentials Competencies: III.1 Explain the interrelationships among theory, practice, and research.
NLN Competencies: Knowledge and Science: Integration of knowledge from nursing and other disciplines.
Nursing/Integrated Concepts: Nursing Process: Implementation
Learning Outcome: 32-3 Explain why hematopoietic enhancers are often administered to patients following
chemotherapy or organ transplant.
MNL Learning Outcome: 4.6.1 Examine the process of hematopoiesis and the pharmacologic treatment of
related deficiencies.
Page Number: 485
Question 4
Type: MCSA
The client receives filgrastim (Neupogen). He asks the nurse, "That is such a funny name; where do you suppose
it comes from?" What is the best response by the nurse?
1. "It comes from the interleukins it stimulates; this one stimulates neuocytes."
, 2. "It comes from the blood cell it stimulates; this one stimulates neutrophils."
3. "It comes from the stem cells it stimulates, such as filgrastims."
4. "It is a complicated process; the drug companies are secretive about it."
Correct Answer: 2
Rationale 1: There aren't any interleukins named neuocytes.
Rationale 2: Colony-stimulating factors (CSFs) are named according to the types of blood cells that they
stimulate. Granulocyte colony-stimulating factor (G-CSF) increases the production of neutrophils, the most
common type of granulocyte.
Rationale 3: There aren't any stem cells named filgrastims.
Rationale 4: Naming of drugs is not a complicated process.
Global Rationale: Colony-stimulating factors (CSFs) are named according to the types of blood cells that they
stimulate. Granulocyte colony-stimulating factor (G-CSF) increases the production of neutrophils, the most
common type of granulocyte. There aren't any interleukins named neuocytes. There aren't any stem cells named
filgrastims. Naming of drugs is not a complicated process.
Cognitive Level: Applying
Client Need: Physiological Integrity
Client Need Sub: Pharmacological and Parenteral Therapies
QSEN Competencies: III.A.1 Demonstrate knowledge of basic scientific methods and processes.
AACN Essentials Competencies: III.1 Explain the interrelationships among theory, practice, and research.
NLN Competencies: Knowledge and Science: Integration of knowledge from nursing and other disciplines.
Nursing/Integrated Concepts: Nursing Process: Implementation
Learning Outcome: 32-2 Explain how aspects of hematopoiesis can be modified by the administration of drugs
that stimulate the production of erythrocytes, leukocytes, and platelets.
MNL Learning Outcome: 4.6.1 Examine the process of hematopoiesis and the pharmacologic treatment of
related deficiencies.
Page Number: 484
Question 5
Type: MCSA
The client is receiving medication for the treatment of anemia. The nurse has taught the client about this drug
and about anemia. The nurse evaluates that learning has occurred when the client makes which statement?
1. "My anemia could be caused by blood loss somewhere, but there are other causes too."
2. "My anemia was caused by drinking too many carbonated beverages with caffeine."
3. "There are many causes for anemia; mine was caused by heart failure and fluid overload."
